MEDS Clinical Medicine (2026)
Clausius Scientific Press, Canada

DOI: 10.23977/medsc.2026.070105
ISSN 2616-1907 Vol. 7 Num. 1

E2F Transcription Factor Family in Cell Cycle Regulation and Tumor Diseases: A Review of Research Progress

Kai Li[1,a,*], Weidong Yang[1,b], Dongqing Wang[1,c]

[1]Department of Urology, Affiliated Hospital of Hebei University, Baoding, Hebei, China
[a]worklk@126.com, [b]yangweidong2025@163.com, [c]858503298@qq.com
**Corresponding author*

Keywords: E2F transcription factor, cell cycle regulation, tumorigenesis, molecular mechanisms, therapeutic target

Abstract: The E2F transcription factor family serves as a pivotal group of regulators in cell cycle control, playing essential roles in cell proliferation, differentiation, apoptosis, and tumorigenesis. This review systematically presents the structural characteristics and functional classification of E2F family members, elucidating their molecular mechanisms in orchestrating cell cycle progression. Special emphasis is placed on the dual roles of different E2F subtypes in tumor initiation and progression, alongside the complex regulatory networks they participate in. Furthermore, by integrating the latest research findings, the review explores the potential of E2F factors as therapeutic targets and evaluates their prospects for clinical translation. Through a comprehensive synthesis of fundamental research and clinical data, this article aims to provide novel insights into the diagnosis and treatment strategies of E2F-related diseases, thereby advancing the understanding of their critical involvement in cancer biology and beyond.

1. Introduction

The E2F transcription factor family is a critical component in the regulation of the cell cycle, influencing key processes such as cell proliferation, differentiation, and apoptosis. This family consists of eight members (E2F1-E2F8), which are classified into activators (E2F1-3) and repressors (E2F4-8). The discovery of E2F factors originated from their interaction with the retinoblastoma (RB) protein, a well-known tumor suppressor that regulates the transition from the G1 to S phase of the cell cycle. Dysregulation of the RB-E2F pathway is a common feature in various cancers, leading to uncontrolled cell division and tumor progression. E2F factors are not only pivotal in cell cycle regulation but have also been implicated in other cellular processes, including DNA repair, metabolic reprogramming, and immune modulation, further underscoring their significance in cancer biology.

Recent studies have highlighted the dual roles of E2F factors in tumorigenesis. For instance, E2F1 is often associated with promoting cell proliferation and survival, while E2F4 and E2F8 may function as tumor suppressors under certain contexts. The interplay between these factors is complex, as they can exhibit context-dependent effects based on the cellular environment and the presence of other

signaling molecules. In cancer, the aberrant activation of E2F target genes can lead to increased proliferation and resistance to apoptosis, contributing to the aggressive nature of tumors. This has prompted researchers to explore E2F factors as potential therapeutic targets, aiming to disrupt their activity to inhibit tumor growth.

The involvement of E2F transcription factors in various cancers has been extensively documented. For example, E2F1 has been shown to regulate genes associated with cell cycle progression and is frequently overexpressed in breast cancer, correlating with poor prognosis. Additionally, E2F3 has been implicated in the progression of colorectal cancer, where it regulates genes essential for cell cycle transition and proliferation. The expression levels of E2F factors, particularly E2F1, E2F3, and E2F4, have been associated with tumor stage, grade, and patient survival across multiple cancer types, including gastric and lung cancers. These findings suggest that E2F transcription factors could serve as valuable biomarkers for cancer prognosis and treatment response.

Moreover, the role of E2F factors extends beyond mere regulation of the cell cycle; they are also involved in the response to DNA damage and the maintenance of genomic stability. For instance, E2F1 has been shown to activate DNA repair pathways, while its dysregulation can lead to genomic instability, a hallmark of cancer. Recent studies have also revealed that E2F factors can influence the immune microenvironment of tumors, affecting the infiltration and activity of immune cells. This highlights the potential of E2F factors not only as therapeutic targets but also as modulators of the tumor immune landscape, providing insights into novel immunotherapeutic strategies.

The emerging understanding of E2F transcription factors as multifaceted regulators in cancer biology has significant implications for therapeutic development. Targeting E2F activity, either through direct inhibition or by modulating upstream signaling pathways, may offer new avenues for cancer treatment. As research continues to elucidate the complex roles of E2F factors in various malignancies, there is a growing interest in their potential as biomarkers and therapeutic targets, paving the way for innovative strategies to combat cancer and improve patient outcomes.

2. Main Body

2.1. Structural Features and Classification of the E2F Transcription Factor Family

2.1.1. Structural Features of Family Members

The E2F transcription factor family is characterized by a conserved structural framework that underpins its diverse regulatory roles in cell cycle control and tumorigenesis. Central to all E2F members is the presence of a highly conserved DNA-binding domain (DBD), which enables specific recognition and binding to E2F-responsive elements within target gene promoters. Adjacent to the DBD is the dimerization domain (DIM), which facilitates heterodimer formation with DP (dimerization partner) proteins, a critical step for enhancing DNA-binding affinity and transcriptional activity. Specifically, E2F1 through E2F6 members form heterodimers with DP proteins, which significantly increases their DNA-binding capacity and transcriptional regulation efficiency. In contrast, the atypical E2Fs, namely E2F7 and E2F8, possess a unique structural configuration featuring two distinct DNA-binding domains, enabling them to bind DNA independently without the need for DP partners. This dual DBD structure confers functional autonomy and distinct regulatory mechanisms compared to canonical E2Fs. Moreover, activator-type E2Fs (E2F1-3a) contain a transcriptional activation domain (TAD) and a marked box domain (MD), which are essential for recruiting coactivators and modulating gene expression. Notably, significant structural divergence exists at the C-terminal regions among E2F family members, which is a determinant of their functional specificity and modes of regulation. These C-terminal variations influence interactions with other proteins, post-translational modifications, and subcellular localization, thereby tailoring

the transcriptional outcomes mediated by each E2F member. Collectively, the conserved core domains combined with variable terminal regions establish a structural basis for the multifaceted roles of E2Fs in cell cycle progression, DNA repair, apoptosis, and tumorigenesis [1][2][3].

2.1.2. Functional Classification and Expression Regulation

Functionally, the E2F family is broadly classified into activators and repressors based on their transcriptional regulatory roles. The activator E2Fs, comprising E2F1, E2F2, and E2F3a, primarily promote the transcription of genes essential for cell cycle progression, particularly those required for the G1/S transition and DNA replication. These activators facilitate the expression of cyclins, DNA polymerases, and other S-phase genes, thereby driving cell proliferation. Conversely, the repressor E2Fs, including E2F3b through E2F8, generally act to suppress transcription of E2F target genes, maintaining cells in a quiescent state or facilitating cell cycle exit. This repression is achieved through recruitment of corepressor complexes and chromatin remodeling factors, contributing to the fine-tuning of cell cycle dynamics. The expression and activity of E2Fs are tightly regulated at multiple levels to ensure cellular homeostasis. Cell cycle-dependent mechanisms govern their expression, with activator E2Fs typically peaking during late G1 and S phases, while repressor E2Fs are expressed more constitutively or during quiescence. Epigenetic modifications, including DNA methylation and histone modifications, modulate E2F gene accessibility and transcriptional output. Additionally, non-coding RNAs such as microRNAs exert post-transcriptional control over E2F mRNA stability and translation, adding another layer of regulation. Recent studies have revealed intricate functional interplay among E2F subtypes, where compensatory and antagonistic relationships form a sophisticated regulatory network. For instance, the loss of one E2F activator can be partially offset by others, while repressor E2Fs can antagonize activator functions to maintain balance. This dynamic network ensures precise control of cell proliferation and prevents aberrant cell cycle progression that could lead to oncogenesis. The complexity of E2F regulation underscores their critical roles in both normal physiology and disease states, including cancer, where dysregulation of E2F expression and function is frequently observed [4][5][3][6].

2.2. E2F in Molecular Mechanisms of Cell Cycle Regulation

2.2.1. Core Role of the RB-E2F Signaling Pathway

The retinoblastoma protein (RB) serves as a pivotal gatekeeper in cell cycle control by directly binding to the transcriptional activation domain of E2F transcription factors, thereby repressing their activity and maintaining cells in the G1 phase. This interaction prevents premature transcription of genes essential for S phase entry and DNA replication. The repression is dynamically regulated by cyclin-dependent kinases (CDKs), which phosphorylate RB at multiple sites, triggering a conformational change that releases E2F factors. Upon phosphorylation-mediated dissociation from RB, free E2Fs activate downstream target genes, including those encoding cyclins, CDKs, and DNA replication enzymes, thus promoting progression into S phase. This RB-E2F axis is finely tuned by diverse upstream signals such as growth factors and DNA damage responses to ensure orderly cell cycle progression. For instance, growth factor stimulation activates CDK4/6-cyclin D complexes, initiating RB phosphorylation and E2F release, whereas DNA damage activates p53-p21 pathways that inhibit CDKs, maintaining RB in a hypophosphorylated, E2F-bound state to arrest the cell cycle. Moreover, recent studies have revealed additional layers of regulation involving ubiquitin-mediated proteolysis of E2Fs by SCF-Cyclin F and APC/C complexes, as well as post-translational modifications modulated by signaling pathways like MEK/ERK, which influence E2F stability and activity. The RB-E2F pathway also integrates with other tumor suppressor networks, such as p53, to

coordinate cell cycle arrest and apoptosis in response to oncogenic stress. Disruption of this pathway is a hallmark of many cancers, where aberrant CDK activity leads to RB inactivation and uncontrolled E2F-driven transcription, fostering malignant proliferation. Furthermore, the RB-E2F axis extends beyond cell cycle regulation, influencing cell fate decisions, differentiation, and DNA repair processes. For example, RBL2/p130 cooperates with E2Fs and chromatin modifiers like GCN5 to regulate WNT ligand expression, thereby guiding tissue specification. Collectively, the RB-E2F signaling pathway constitutes a central molecular hub that integrates multiple signals to regulate cell cycle transitions, maintain genomic stability, and suppress tumorigenesis, underscoring its critical role in cellular homeostasis and disease [7][8][9][10][11][12][13][14][15][1].

2.2.2. E2F Target Genes and Their Functional Networks

E2F transcription factors orchestrate the expression of an extensive repertoire of target genes, exceeding one thousand, which encompass critical regulators of cell cycle progression such as cyclins, cyclin-dependent kinases (CDKs), DNA replication machinery components, and DNA repair enzymes. This broad target gene spectrum reflects the multifaceted roles of E2Fs in coordinating cell proliferation, genome maintenance, and cellular differentiation. Distinct E2F family members exhibit both overlapping and unique target gene profiles, enabling functional specialization within the E2F network. Activator E2Fs (E2F1-3a) predominantly induce genes promoting S phase entry and DNA synthesis, whereas repressor E2Fs (E2F3b-E2F8) modulate transcriptional repression to fine-tune cell cycle progression and prevent aberrant proliferation. Advanced genomic techniques such as ChIP-seq and transcriptome analyses have revealed heterogeneity in E2F target gene expression across different cell types and tissues, highlighting context-dependent regulatory mechanisms. For example, in cancer stem cells, dysregulated E2F activity governs plasticity and cell cycle dynamics by modulating DNA replication factors and cell cycle checkpoints. Additionally, E2Fs regulate genes involved in metabolic pathways, apoptosis, and chromatin remodeling, indicating their broader influence beyond classical cell cycle control. Post-transcriptional regulators like IGF2BP1 further enhance the stability and expression of E2F-driven transcripts, acting as super-enhancers of E2F target gene expression in cancer. Moreover, E2F target gene signatures have been identified as prognostic biomarkers in various malignancies, including hepatocellular carcinoma, breast cancer, and pancreatic adenocarcinoma, linking their expression patterns to tumor aggressiveness, immune microenvironment modulation, and therapeutic responses. Functional studies have also uncovered feedback loops involving E2F-regulated genes such as KIF26A and CKS2 that promote cell cycle progression and tumorigenesis. In sum, the E2F target gene network constitutes a complex and dynamic regulatory system that integrates diverse cellular signals to control proliferation, differentiation, and tumorigenesis, with ongoing research continuing to elucidate its intricate layers of regulation and clinical implications [12][7][16][17][18][19][20][21][22][2].

2.3. Dual Roles of E2F in Tumorigenesis and Development

2.3.1. Pro-tumorigenic Mechanisms

The E2F transcription factor family, particularly the activator members E2F1, E2F2, and E2F3, plays a pivotal role in driving cell cycle progression by promoting the transcription of genes essential for DNA synthesis and S-phase entry. Overactivation or overexpression of these E2Fs leads to dysregulated cell cycle control, a hallmark of tumorigenesis. For example, in hepatocellular carcinoma (HCC), E2F1 is frequently upregulated independent of tumor stage, correlating with poor patient survival and aggressive tumor features such as increased neoplasm histologic grade and elevated alpha-fetoprotein levels [23]. Similarly, E2F8, an atypical E2F family member, is

significantly overexpressed in HCC tumor tissues and peripheral blood mononuclear cells of patients, and its elevation independently predicts worse overall and progression-free survival [24]. These findings underscore the role of E2F1-3 and E2F8 in promoting tumor cell proliferation and progression.

Mechanistically, the overactivation of E2F1-3 disrupts the tightly regulated G1/S checkpoint, leading to uncontrolled entry into S phase and subsequent genomic instability. This instability arises partly because E2Fs regulate not only cell cycle genes but also genes involved in DNA replication and repair pathways. For instance, constitutively active E2F1 enhances homologous recombination-mediated DNA double-strand break repair while suppressing non-homologous end joining, thereby influencing genome stability in complex ways that may paradoxically promote tumorigenesis [25]. Furthermore, E2Fs can transcriptionally activate genes implicated in angiogenesis and metastasis. E2F7 and E2F8, while atypical repressors, have been shown to regulate oncogenic pathways such as epithelial-mesenchymal transition (EMT), NFκB, STAT3, and angiogenesis, contributing to tumor progression in high-grade glioma [26]. In gastric cancer, E2Fs modulate the tumor microenvironment by influencing immune cell infiltration and stromal activation, which can facilitate tumor growth and immune evasion [27].

Additionally, E2F activity is influenced by co-factors and post-translational modifications that further fine-tune their oncogenic potential. For example, FOXK1, when O-GlcNAcylated, recruits the tumor suppressor BAP1 to E2F target genes, promoting a transcriptional environment conducive to cancer cell proliferation [28]. The interplay between E2Fs and chromatin remodelers such as ARID3A and ARID3B also modulates the expression of E2F target genes like cyclin E1 and CDC2, enhancing tumor cell growth and survival [18]. Moreover, oncogenic feedback loops involving E2Fs and proteins such as ATAD2 and TRIM25 have been identified in colorectal cancer, where E2Fs promote ATAD2 expression, which in turn co-activates E2Fs, driving tumor progression [29].

Clinically, amplification or overexpression of E2F1-3 has been observed in various cancers and is often associated with poor prognosis, aggressive tumor behavior, and resistance to therapy. For instance, in clear cell renal cell carcinoma (ccRCC), elevated expression of E2F1 to E2F4 and E2F6 to E2F8 correlates with advanced tumor stage, higher grade, and worse survival outcomes [30]. Similarly, in pancreatic adenocarcinoma, high levels of E2F1/2/3/7/8 are linked to shorter overall and disease-free survival, highlighting their potential as prognostic biomarkers and therapeutic targets [31]. Thus, the pro-tumorigenic mechanisms of E2F1-3 and other family members involve deregulated cell cycle progression, promotion of genomic instability, and modulation of tumor microenvironment factors that collectively drive tumor initiation, growth, and metastasis.

2.3.2. Tumor Suppressive Mechanisms

While many E2F family members exhibit oncogenic properties, certain members, notably the atypical repressors E2F7 and E2F8, as well as the classical activator E2F1 under specific contexts, demonstrate tumor suppressive functions. E2F7 and E2F8 lack the canonical DP dimerization domain and act primarily as transcriptional repressors, antagonizing the activity of E2F1-3. Their repressive function is critical in maintaining proper cell cycle control and genomic stability. For example, in hepatocytes, combined deletion of RB and E2F7/8 results in enhanced proliferation and malignant progression of liver tumors, indicating that E2F7/8 cooperate with RB to suppress tumorigenesis [32]. Intriguingly, loss of either E2F7 or E2F8 alone can prevent pituitary tumor formation in RB-deficient mice, suggesting a complex, tissue-specific duality in their roles.

E2F1 exemplifies a “double-edged sword” effect in cancer biology. Although its overexpression promotes cell proliferation, excessive E2F1 levels can induce apoptosis, acting as a fail-safe mechanism against uncontrolled cell growth. This pro-apoptotic function is mediated through activation of tumor suppressor pathways, including ARF-p53 signaling, which triggers cell cycle

arrest or programmed cell death in response to oncogenic stress [33]. Moreover, E2F1 can activate promoters of tumor suppressor genes such as ARF and TAp73 specifically under deregulated conditions, but not during physiological proliferation, thereby enabling selective tumor suppression [34]. This selective activation provides a mechanism by which E2F1 balances proliferation and apoptosis, preventing malignant transformation.

Recent studies have also highlighted the context-dependent roles of E2Fs within the tumor microenvironment (TME). In gastric cancer, distinct E2F expression patterns correlate with differences in immune cell infiltration and stromal activation, influencing patient prognosis and response to immunotherapy [27]. High E2F scores associate with improved immune responses and survival, suggesting that E2Fs can modulate anti-tumor immunity. Furthermore, the tumor suppressor p53 indirectly regulates E2F activity via the p21-RB pathway, enforcing cell cycle arrest and preventing aberrant proliferation [13]. Loss of this regulatory axis leads to uncontrolled E2F activity and tumor progression.

Additionally, post-translational modifications and feedback loops contribute to the tumor suppressive functions of E2Fs. For instance, the TFDP1 gene, encoding DP1 (a heterodimeric partner of E2Fs), is itself a target of deregulated E2F activity, forming a feedback loop that maintains balanced E2F function and prevents excessive proliferation [35]. The interplay between RB family proteins and E2Fs is also critical; RB binds and represses E2F transcriptional activity, and its inactivation releases E2Fs to drive cell cycle progression. However, RB also exerts E2F-independent tumor suppressive roles, highlighting the complexity of this regulatory network [36].

In summary, the tumor suppressive mechanisms of E2Fs involve antagonism of activator E2Fs by atypical repressors (E2F7/8), induction of apoptosis by high levels of E2F1, and integration within tumor suppressor pathways such as p53-p21-RB signaling. These mechanisms act as intrinsic safeguards against tumorigenesis. However, the dual roles of E2Fs are highly context-dependent, influenced by tissue type, tumor microenvironment, and genetic background, underscoring the complexity of targeting E2F pathways therapeutically. Understanding these nuanced roles is crucial for developing strategies that can selectively inhibit the oncogenic functions of E2Fs while preserving or enhancing their tumor suppressive activities.

2.4. E2F as a Therapeutic Target: Research Progress

2.4.1. Development of Small-Molecule Inhibitors Targeting E2F

The E2F family of transcription factors plays a pivotal role in cell cycle regulation, and their aberrant activation is implicated in tumorigenesis across diverse cancer types. Consequently, targeting E2F activity has emerged as a promising therapeutic strategy. Several small-molecule inhibitors have been reported to interfere with E2F function by disrupting the critical interactions between E2F and DNA or its heterodimeric partner DP, thereby suppressing E2F-driven transcriptional activity. These inhibitors act by preventing E2F-DP dimerization or blocking E2F binding to promoter regions of cell cycle-related genes, effectively halting the transcription of genes essential for S-phase entry and DNA replication. For example, 20(S)-ginsenoside Rg3 has been demonstrated to bind directly to E2F at the heterodimeric domain, disrupting E2F-DP heterodimer formation and inhibiting downstream gene expression, resulting in G1/S cell cycle arrest and suppressed proliferation in gastric cancer models [37]. Similarly, novel macrocyclic peptides have been developed to inhibit cyclin A/B RxL motif interactions that modulate E2F activity, selectively inducing apoptosis in cancers with compromised G1-S checkpoints [38]. The discovery of mitochondrial-targeted small molecules like IR-817, which induce cell cycle arrest through the E2F/Cyclin/CDK pathway, further underscores the therapeutic potential of small-molecule E2F inhibitors [39]. The development of these inhibitors has been accelerated by structure-based drug

design and high-throughput screening techniques, enabling the identification of compounds with high specificity and efficacy. Moreover, inhibitors targeting upstream regulators of E2F, such as CDK4/6 inhibitors (e.g., abemaciclib and PD-0332991), indirectly suppress E2F activity by maintaining the retinoblastoma protein (Rb) in its hypophosphorylated, active state, thereby sequestering E2F and preventing transcriptional activation of cell cycle genes [40][41][42]. These small molecules have shown clinical efficacy in hormone receptor-positive breast cancer and are being explored in other malignancies. Despite these advances, challenges remain in achieving cancer cell specificity and overcoming resistance mechanisms, such as Rb loss or E2F deregulation independent of Rb control. Nonetheless, the continued refinement of small-molecule inhibitors targeting E2F or its regulatory network holds promise for novel cancer therapeutics.

2.4.2. Gene Therapy Strategies

Gene therapy approaches targeting specific E2F family members have shown encouraging preclinical antitumor effects by silencing aberrant E2F expression. RNA interference technologies, including siRNA and shRNA, have been employed to selectively downregulate oncogenic E2Fs such as E2F1 and E2F7, resulting in inhibited proliferation, induced apoptosis, and impaired metastatic potential in various cancer models. For instance, siRNA-mediated silencing of E2F2 in meibomian gland carcinoma cells reversed gene silencing caused by DNA methylation, suppressing malignant progression and suggesting a therapeutic avenue for epigenetically regulated E2F members [43]. Similarly, knockdown of E2F7 in high-grade glioma cells enhanced radiosensitivity and reduced tumor growth, highlighting the therapeutic relevance of targeting specific E2Fs [26]. Advances in genome editing technologies, particularly CRISPR-Cas9, have opened new possibilities for precise modulation of E2F gene expression. A genome-wide CRISPR screen identified E2F1 as a critical regulator of aristolochic acid-induced nephrotoxicity, and targeted editing of E2F1 expression attenuated apoptosis in renal cells, demonstrating the feasibility of CRISPR-based interventions [44]. Such gene editing strategies offer the potential for durable and specific suppression of oncogenic E2F activity, overcoming limitations of transient RNA interference. However, challenges including delivery efficiency, off-target effects, and immune responses must be addressed before clinical translation. Overall, gene therapy targeting E2F transcription factors represents a promising approach to modulate aberrant cell cycle regulation in cancer, with ongoing research focused on optimizing delivery systems and ensuring safety.

2.4.3. Combination Therapy Strategies

Combining E2F-targeted therapies with conventional chemotherapy or immunotherapy has demonstrated synergistic antitumor effects, enhancing treatment efficacy and overcoming resistance. CDK4/6 inhibitors, which indirectly suppress E2F activity, have been effectively combined with endocrine therapy in hormone receptor-positive breast cancer, improving progression-free survival [41][45]. Beyond monotherapy, combining CDK4/6 inhibitors with CDK2 inhibitors has shown promise in overcoming acquired resistance by more comprehensively inhibiting E2F-driven cell cycle progression [46]. Moreover, small-molecule inhibitors targeting E2F regulators such as BRD9 and PRMT5 have been combined with immunomodulatory drugs to potentiate apoptosis and suppress oncogenic transcriptional programs in multiple myeloma, indicating the benefit of dual targeting of epigenetic and transcriptional pathways [47][48]. In the context of immunotherapy, E2F expression profiles have been used to stratify patients for immune checkpoint inhibitor responsiveness, with certain E2F-related gene signatures correlating with immune infiltration and therapeutic outcomes in gastric and neuroblastoma cancers [49][50]. Additionally, oncolytic viruses expressing variant IL-2 cytokines have been shown to enhance tumor-infiltrating lymphocyte and natural killer cell

cytotoxicity in ovarian cancer, suggesting that modulation of the tumor microenvironment alongside E2F-targeted approaches could improve immunotherapeutic efficacy [51][52]. These combination strategies exploit the multifaceted role of E2Fs in cell proliferation, apoptosis, and immune regulation, aiming to achieve durable tumor control. Clinical trials are underway to evaluate the safety and efficacy of these combinations, with the goal of integrating E2F-targeted therapies into precision medicine frameworks tailored to individual tumor E2F expression profiles and resistance mechanisms.

3. Conclusions

In conclusion, the E2F transcription factor family stands as a pivotal regulator within the intricate network governing cell cycle progression and diverse pathological processes. From an expert perspective, the dualistic roles of various E2F subtypes in tumorigenesis underscore the complexity of their biological functions and highlight the nuanced balance between oncogenic and tumor-suppressive activities. This duality not only enriches our understanding of cancer biology but also lays a robust theoretical foundation for the development of targeted therapeutic interventions.

However, translating these insights into effective clinical strategies remains challenging. Current approaches targeting E2F factors often grapple with issues of specificity, leading to off-target effects and limited therapeutic windows. This underscores a critical need for the design and implementation of more precise intervention modalities that can discriminate among E2F subtypes and their context-dependent activities. Achieving such specificity will likely require a deeper mechanistic understanding of E2F regulation within distinct cellular and disease contexts.

Looking forward, future research must prioritize elucidating the precise regulatory mechanisms of E2F factors across various pathological backgrounds. This includes dissecting tissue- and disease-specific signaling pathways that modulate E2F activity, which will be instrumental in crafting tailored, organ-specific regulatory strategies. Such focused investigations will enhance the therapeutic index of E2F-targeted treatments and minimize unintended systemic effects.

Moreover, the integration of multi-omics data—encompassing genomics, transcriptomics, proteomics, and epigenomics—combined with advanced artificial intelligence and machine learning techniques, promises to accelerate the depth and breadth of E2F-related research. These technologies can uncover hidden patterns, predict functional outcomes, and identify novel regulatory nodes within the E2F network, thereby facilitating the translation of basic research findings into clinically actionable interventions.

Balancing the diverse research perspectives and findings, it is evident that while significant progress has been made in understanding the multifaceted roles of E2F transcription factors, a concerted effort integrating molecular biology, computational analytics, and clinical sciences is essential. This multidisciplinary approach will not only refine our conceptual frameworks but also drive the innovation of precision medicine strategies targeting E2F pathways. Ultimately, such advancements hold the promise of improving patient outcomes across a spectrum of diseases where E2F dysregulation plays a critical role.

References

[1] Chan AB, Huber AL, Lamia KA. Cryptochromes modulate E2F family transcription factors. Sci Rep. 2020;10(1):4077. Published 2020 Mar 5. doi:10.1038/s41598-020-61087-y https://pubmed.ncbi.nlm.nih.gov/32139766/

[2] Li FF, Wang Y, Gu JH, Zhang YM, Liu FS, Ni ZH. E2F family play important roles in tumorigenesis. Yi Chuan. 2023;45(7):580-592. doi:10.16288/j.yczz.23-029 https://pubmed.ncbi.nlm.nih.gov/37503582/

[3] Sun M, Ji Y, Zhang G, Li Y, Dong F, Wu T. Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets. Biomed Pharmacother. 178:117147. doi:10.1016/j.biopha.2024.117147 https://pubmed.ncbi.nlm.nih.gov/39053422/

[4] Wang Q, Liu J, Cheang I, et al. Comprehensive Analysis of the E2F Transcription Factor Family in Human Lung

Adenocarcinoma. Int J Gen Med. 15:5973-5984. Published 2022 None. doi:10.2147/IJGM.S369582 https://pubmed.ncbi.nlm.nih.gov/35811776/
[5] Wang H, Wang X, Xu L, Zhang J, Cao H. Integrated analysis of the E2F transcription factors across cancer types. Oncol Rep. 2020;43(4):1133-1146. doi:10.3892/or.2020.7504 https://pubmed.ncbi.nlm.nih.gov/32323836/
[6] Shi J. Early 2-Factor Transcription Factors Associated with Progression and Recurrence in Bevacizumab-Responsive Subtypes of Glioblastoma. Cancers (Basel). 2024;16(14). Published 2024 Jul 14. doi:10.3390/cancers16142536 https://pubmed.ncbi.nlm.nih.gov/39061176/
[7] Zheng WJ, Li WQ, Peng Y, et al. E2Fs co-participate in cadmium stress response through activation of MSHs during the cell cycle. Front Plant Sci. 13:1068769. Published 2022 None. doi:10.3389/fpls.2022.1068769 https://pubmed.ncbi.nlm.nih.gov/36531377/
[8] Lee GE, Jeung D, Chen W, et al. MEKs/ERKs-mediated FBXO1/E2Fs interaction interference modulates G1/S cell cycle transition and cancer cell proliferation. Arch Pharm Res. 2023;46(1):44-58. doi:10.1007/s12272-023-01426-5 https://pubmed.ncbi.nlm.nih.gov/36607545/
[9] Villamar-Cruz O, Loza-Mejía MA, Vivar-Sierra A, et al. A PTP1B-Cdk3 Signaling Axis Promotes Cell Cycle Progression of Human Glioblastoma Cells through an Rb-E2F Dependent Pathway. Mol Cell Biol. 2023;43(12):631-649. doi:10.1080/10985549.2023.2273193 https://pubmed.ncbi.nlm.nih.gov/38014992/
[10] Emanuele MJ, Enrico TP, Mouery RD, Wasserman D, Nachum S, Tzur A. Complex Cartography: Regulation of E2F Transcription Factors by Cyclin F and Ubiquitin. Trends Cell Biol. 2020;30(8):640-652. doi:10.1016/j.tcb.2020.05.002 https://pubmed.ncbi.nlm.nih.gov/32513610/
[11] Militi S, Nibhani R, Jalali M, Pauklin S. RBL2-E2F-GCN5 guide cell fate decisions during tissue specification by regulating cell-cycle-dependent fluctuations of non-cell-autonomous signaling. Cell Rep. 2023;42(9):113146. doi:10.1016/j.celrep.2023.113146 https://pubmed.ncbi.nlm.nih.gov/37725511/
[12] Segeren HA, van Rijnberk LM, Moreno E, et al. Excessive E2F Transcription in Single Cancer Cells Precludes Transient Cell-Cycle Exit after DNA Damage. Cell Rep. 2020;33(9):108449. doi:10.1016/j.celrep.2020.108449 https://pubmed.ncbi.nlm.nih.gov/33264622/
[13] Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29(5):946-960. doi:10.1038/s41418-022-00988-z https://pubmed.ncbi.nlm.nih.gov/35361964/
[14] Zhou Y, Nakajima R, Shirasawa M, et al. Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression. Biology (Basel). 2023;12(12). Published 2023 Dec 11. doi:10.3390/biology12121511 https://pubmed.ncbi.nlm.nih.gov/38132337/
[15] Zhang M, Kim S, Yang HW. Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity. Nat Commun. 2023;14(1):7847. Published 2023 Nov 29. doi:10.1038/s41467-023-43716-y https://pubmed.ncbi.nlm.nih.gov/38030655/
[16] Manickavinayaham S, Dennehey BK, Johnson DG. Direct Regulation of DNA Repair by E2F and RB in Mammals and Plants: Core Function or Convergent Evolution? Cancers (Basel). 2021;13(5). Published 2021 Feb 24. doi:10.3390/cancers13050934 https://pubmed.ncbi.nlm.nih.gov/33668093/
[17] Xu H, Liang S, Hu J, Liu W, Dong Z, Wei S. Deltex E3 ubiquitin ligase 3 inhibits colorectal cancer cell growth and regulates cell cycle progression via upregulating E2F transcription factor 1. Mol Biol Rep. 2022;49(3):1661-1668. doi:10.1007/s11033-021-06916-7 https://pubmed.ncbi.nlm.nih.gov/35098394/
[18] Saadat KASM, Lestari W, Pratama E, et al. Distinct and overlapping roles of ARID3A and ARID3B in regulating E2F-dependent transcription via direct binding to E2F target genes. Int J Oncol. 2021;58(4). doi:10.3892/ijo.2021.5192 https://pubmed.ncbi.nlm.nih.gov/33649863/
[19] Øvrebø JI, Bradley-Gill MR, Zielke N, et al. Translational control of E2f1 regulates the Drosophila cell cycle. Proc Natl Acad Sci U S A. 2022;119(4). doi:10.1073/pnas.2113704119 https://pubmed.ncbi.nlm.nih.gov/35074910/
[20] Chida K, Oshi M, Roy AM, et al. E2F target score is associated with cell proliferation and survival of patients with hepatocellular carcinoma. Surgery. 2023;174(2):307-314. doi:10.1016/j.surg.2023.04.030 https://pubmed.ncbi.nlm.nih.gov/37198038/
[21] Nikonezhad B, Lotfian M, Manavi N, Zamani A, Mahdevar M. Insights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses. Cancer Cell Int. 2025;25(1):203. Published 2025 Jun 6. doi:10.1186/s12935-025-03839-2 https://pubmed.ncbi.nlm.nih.gov/40481544/
[22] Xie D, Pei Q, Li J, Wan X, Ye T. Emerging Role of E2F Family in Cancer Stem Cells. Front Oncol. 11:723137. Published 2021 None. doi:10.3389/fonc.2021.723137 https://pubmed.ncbi.nlm.nih.gov/34476219/
[23] Ye WY, Lu HP, Li JD, et al. Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues. Cancer Biother Radiopharm. 2023;38(10):684-707. doi:10.1089/cbr.2020.4342 https://pubmed.ncbi.nlm.nih.gov/34619053/
[24] Lü Y, Zhang J, Li L, Li S, Yang Z. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report. Biosci Rep. 2020;40(2). doi:10.1042/BSR20193212

https://pubmed.ncbi.nlm.nih.gov/31990034/
[25] Pei X, Du E, Sheng Z, Du W. Rb family-independent activating E2F increases genome stability, promotes homologous recombination, and decreases non-homologous end joining. Mech Dev. 162:103607. doi:10.1016/j.mod.2020.103607 https://pubmed.ncbi.nlm.nih.gov/32217105/
[26] Yu H, Li Z, Wang M. Expression and prognostic role of E2F transcription factors in high-grade glioma. CNS Neurosci Ther. 2020;26(7):741-753. doi:10.1111/cns.13295 https://pubmed.ncbi.nlm.nih.gov/32064771/
[27] Li F, Yan J, Leng J, et al. Expression patterns of E2Fs identify tumor microenvironment features in human gastric cancer. PeerJ. 12:e16911. Published 2024 None. doi:10.7717/peerj.16911 https://pubmed.ncbi.nlm.nih.gov/38371373/
[28] Ahmed O, Masclef L, Iannantuono N, et al. O-GlcNAcylation of FOXK1 co-opts BAP1 to orchestrate the E2F pathway and promotes oncogenesis. Nat Commun. 2025;16(1):5959. Published 2025 Jul 1. doi:10.1038/s41467-025-61022-7 https://pubmed.ncbi.nlm.nih.gov/40593803/
[29] Tong Y, Li J, Peng M, et al. ATAD2 drives colorectal cancer progression by regulating TRIM25 expression via a positive feedback loop with E2F transcriptional factors. Biochem Biophys Res Commun. 594:146-152. doi:10.1016/j.bbrc.2022.01.036 https://pubmed.ncbi.nlm.nih.gov/35085891/
[30] Liu ZG, Su J, Liu H, et al. Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma. Oncol Lett. 2022;24(4):351. Published 2022 Oct. doi:10.3892/ol.2022.13471 https://pubmed.ncbi.nlm.nih.gov/36168311/
[31] Luo L, Zhang G, Wu T, Wu G. Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma. Med Sci Monit. 27:e933443. Published 2021 Nov 20. doi:10.12659/MSM.933443 https://pubmed.ncbi.nlm.nih.gov/34799547/
[32] Moreno E, Pandit SK, Toussaint MJM, et al. Atypical E2Fs either Counteract or Cooperate with RB during Tumorigenesis Depending on Tissue Context. Cancers (Basel). 2021;13(9). Published 2021 Apr 23. doi:10.3390/cancers13092033 https://pubmed.ncbi.nlm.nih.gov/33922435/
[33] Seo J, Seong D, Lee SR, Oh DB, Song J. Post-Translational Regulation of ARF: Perspective in Cancer. Biomolecules. 2020;10(8). Published 2020 Aug 4. doi:10.3390/biom10081143 https://pubmed.ncbi.nlm.nih.gov/32759846/
[34] Kurayoshi K, Tanaka M, Nakajima R, et al. Utility of Tumor Suppressor E2F Target Gene Promoter Elements to Drive Gene Expression Specifically in Cancer Cells. Cells. 2025;14(24). Published 2025 Dec 9. doi:10.3390/cells14241953 https://pubmed.ncbi.nlm.nih.gov/41439972/
[35] Nakajima R, Deguchi R, Komori H, et al. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochem Biophys Res Commun. 663:154-162. doi:10.1016/j.bbrc.2023.04.092 https://pubmed.ncbi.nlm.nih.gov/37141667/
[36] Janostiak R, Torres-Sanchez A, Posas F, de Nadal E. Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies. Cancers (Basel). 2022;14(5). Published 2022 Feb 28. doi:10.3390/cancers14051265 https://pubmed.ncbi.nlm.nih.gov/35267571/
[37] Li F, Cai C, Wang F, et al. 20(S)-ginsenoside Rg3 suppresses gastric cancer cell proliferation by inhibiting E2F-DP dimerization. Phytomedicine. 141:156740. doi:10.1016/j.phymed.2025.156740 https://pubmed.ncbi.nlm.nih.gov/40252583/
[38] Singh S, Gleason CE, Fang M, et al. Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors. Nature. 2025;646(8085):734-745. doi:10.1038/s41586-025-09433-w https://pubmed.ncbi.nlm.nih.gov/40836083/
[39] Sun C, Wang J, Xia T, et al. Mitochondrion-Targeted NIR Therapeutic Agent Suppresses Melanoma by Inducing Apoptosis and Cell Cycle Arrest via E2F/Cyclin/CDK Pathway. Pharmaceuticals (Basel). 2022;15(12). Published 2022 Dec 19. doi:10.3390/ph15121589 https://pubmed.ncbi.nlm.nih.gov/36559040/
[40] Hu J, Shen J, Sun J. CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer. Biomed Pharmacother. 125:109870. doi:10.1016/j.biopha.2020.109870 https://pubmed.ncbi.nlm.nih.gov/32032891/
[41] Yao Y, Deng S, Ng JF, et al. Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth. Haematologica. 2025;110(1):153-162. Published 2025 Jan 1. doi:10.3324/haematol.2024.285491 https://pubmed.ncbi.nlm.nih.gov/39049606/
[42] Glaviano A, Wander SA, Baird RD, et al. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat. 76:101103. doi:10.1016/j.drup.2024.101103 https://pubmed.ncbi.nlm.nih.gov/38943828/
[43] Wang W, Wang H, Liu X, et al. E2F2(E2F transcription factor 2) as a potential therapeutic target in meibomian gland carcinoma: evidence from functional and epigenetic studies. BMC Cancer. 2025;25(1):880. Published 2025 May 16. doi:10.1186/s12885-025-13833-6 https://pubmed.ncbi.nlm.nih.gov/40380087/
[44] Liu Z, Gao H, Li G, et al. Genome-wide CRISPR-based screen identifies E2F transcription factor 1 as a regulator and therapeutic target of aristolochic acid-induced nephrotoxicity. Environ Int. 195:109234. doi:10.1016/j.envint.2024.109234 https://pubmed.ncbi.nlm.nih.gov/39724681/
[45] Wander SA, O'Brien N, Litchfield LM, et al. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical

Insights Related to Abemaciclib. Oncologist. 2022;27(10):811-821. doi:10.1093/oncolo/oyac138 https://pubmed.ncbi.nlm.nih.gov/35917168/
[46] Armand J, Kim S, Kim K, et al. Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. Elife. 14. Published 2025 Dec 29. doi:10.7554/eLife.104545 https://pubmed.ncbi.nlm.nih.gov/41459763/
[47] Chowdhury B, Garg S, Ni W, et al. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma. Cancers (Basel). 2024;16(7). Published 2024 Mar 28. doi:10.3390/cancers16071319 https://pubmed.ncbi.nlm.nih.gov/38610997/
[48] Sloan SL, Brown F, Long M, et al. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood. 2023;142(10):887-902. doi:10.1182/blood.2022019419 https://pubmed.ncbi.nlm.nih.gov/37267517/
[49] Huang W, Zhang Y, Chen S, et al. Personalized immune subtypes based on machine learning predict response to checkpoint blockade in gastric cancer. Brief Bioinform. 2023;24(1). doi:10.1093/bib/bbac554 https://pubmed.ncbi.nlm.nih.gov/36572651/
[50] Cai D, Xu H, He S, Xu D, Li L. Precision prognostication in neuroblastomas via clinically validated E2F activity signatures. Front Immunol. 16:1612667. Published 2025 None. doi:10.3389/fimmu.2025.1612667 https://pubmed.ncbi.nlm.nih.gov/40599792/
[51] Yang Q, Vafaei S, Falahati A, et al. Decoding Bromodomain and Extra-Terminal Domain Protein-Mediated Epigenetic Mechanisms in Human Uterine Fibroids. Int J Mol Sci. 2025;26(24). Published 2025 Dec 17. doi:10.3390/ijms262412144 https://pubmed.ncbi.nlm.nih.gov/41465569/
[52] Quixabeira DCA, Pakola S, Jirovec E, et al. Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. Cancer Gene Ther. 2023;30(12):1679-1690. doi:10.1038/s41417-023-00674-3 https://pubmed.ncbi.nlm.nih.gov/37949944/